SINGAPORE (Feb 8): Trendlines Medical Singapore, a subsidiary of Israeli company The Trendlines Group, is partnering Singapore-based investor Ozi Amanat’s venture capital firm, K2 Global, to collaborate in SPRING SEEDS Capital’s (SSC) $100 million investment allocation via the Startup SG Equity scheme.

Under the Startup SG Equity scheme, SSC supports early-stage startups across the technology and industry domain areas, and catalyses private-sector investments for startups via government equity co-investment.

The scheme announced its $100 million investment allocation in July 2017 to groom start-ups, and issued a call to its appointed partners to co-invest in the health & biomedical sciences and other fields.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Related Stories

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook